

**A. Agusti** has received reimbursements, fees, or funding from GlaxoSmithKline, Almirall, AstraZeneca, Boehringer Ingelheim, Roche, Chiesi, Nycomed, Novartis, Takeda, and Procter & Gamble.

**P. Bakke** has received lecture fees from AstraZeneca, GlaxoSmithKline and NycoMed; has participated in clinical research studies sponsored by GlaxoSmithKline, Pfizer and Boehringer Ingelheim.

**P.M.A. Calverley** has received consulting fees from AstraZeneca, GlaxoSmithKline, Nycomed, Novartis and Pfizer; speaking fees from GlaxoSmithKline and Nycomed; and grant support from Boehringer Ingelheim and GlaxoSmithKline. He is a board member for GlaxoSmithKline, Boehringer-Ingelheim, Nycomed and the Department of Health Respiratory Programme Board. He has provided expert testimony for Forest. P.M.A. Calverley has received honoraria for advising on the conduct and analysis of clinical trial data from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Nycomed and Novartis. He has also spoken at meetings supported by these companies. Support for travel to meetings has been provided by AstraZeneca.

**B. Celli** has received grants to the pulmonary division and works into complete research studies from GlaxoSmithKline, Boehringer Ingelheim, Forrest Medical, AstraZeneca and Aeris. He has also served on advisory boards for GlaxoSmithKline, Boehringer Ingelheim, Almirall, AstraZeneca, Aeris and Deep Breeze. B. Celli has received speaker fees from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Almirall and Esteve.

**H.O. Coxson** has received an honorarium for serving on the steering committee for the ECLIPSE project for GlaxoSmithKline. In addition he was the co-investigator on two multicentre studies sponsored by GlaxoSmithKline and has received travel expenses to attend meetings related to the project. H.O. Cox has three contract service agreements with GlaxoSmithKline to quantify the CT scans in subjects with COPD and a service agreement with Spiration Inc to measure changes in lung volume in subjects with severe emphysema. He is also the co-investigator (D Sin PI) on a Canadian Institutes of Health–Industry (Wyeth) partnership grant, and has received a fee for speaking at a conference and related travel expenses from AstraZeneca (Australia).

**C. Crim** is an employee and shareholder of GlaxoSmithKline, the sponsor of ECLIPSE.

**L.D. Edwards** is an employee and shareholder of GlaxoSmithKline, the sponsor of ECLIPSE..

**D.A. Lomas** has received grant funding, honoraria and travel expenses from GlaxoSmithKline and serves as Chair for the Respiratory Therapy Area Board of GlaxoSmithKline.

**S. Rennard** has received tobacco industry funding. Specifically, he has received funding from the tobacco industry for studies relating to harm reduction and to the impact of tobacco smoke on stem cells. He has also consulted with RJ Reynolds without personal fee on the topic of harm reduction and received funding from RJ Reynolds to evaluate the effect of a harm reduction product in normal smokers (1996) and in subjects with chronic bronchitis (1999) and to assess the effect of smoking cessation on lower respiratory tract inflammation (2000). S. Rennard has participated in a Philip Morris multicenter study to assess biomarkers of smoke exposure (2002) and received funding for a clinical trial from the Institute for Science and Health (2005), which receives support from the tobacco industry, to evaluate biomarkers in exhaled breath associated with smoking cessation and reduction. This study was

supplemented with funding from Lorillard and RJ Reynolds. He has also received a grant from the Philip Morris External Research Program (2005) to assess the impact of cigarette smoking on circulating stem cells in the mouse. In addition he has consulted with RJ Reynolds on the topic of harm reduction until 2007, but did not receive personal remuneration for this. There are no active tobacco-industry funded projects. All ties with tobacco industry companies and entities supported by tobacco companies were terminated in 2007.

S. Rennard has received reimbursement for attending a symposium, speaking and/or consulting from: AAAAI, ABIM, Able Associates, Adelpia Research, Align2 Acton, Almirall, APT Pharma, Aradigm, Argenta, Astra-Zeneca, ATS, Beilenson, Boehringer Ingelheim, Biostrategies, BoomCom, Britnall and Nicolini, California Society of Pulmonary Rehabilitation, Capital Research, Chiesi, Clarus Acuity, Clinical Advisors, CME Incite, CommonHealth, Complete Medical Group, Consensus Medical, Consult Complete, Convergent Health Solutions, COPForum, COPD Foundation, DataMonitor, Decision Resources, Defined Health, Dey, Dunn Group, Easton Associates, Elevation Pharma, Enterprise Analysis, Equinox, Forest, France Foundation, Frankel Group, Fulcrum, Gerson Lehman, Globe Life Sciences, GSK, Guidepoint Global, Health Advanced, Hoffman LaRoche, Informed, Inspire, Insyght, IntraMed, Johnson and Johnson, KOL Connection, Kyorin Pharma, University of Southern California, Lerrink Swan, M. Pankove, McKinsey, MDRxFinancial, MedaCorp, Medimmune, Merck, Mpex, Navigant, Network for Continuing Education (CHARM), Novartis, Nuvis, Nycomed, Oriel, Osterman, Otsuka, Pearl, Penn Technology, Pennside, Pfizer, PharmaVentures, Pharmaxis, Phone Call IMS, Pick Research, Prescott, Price Waterhouse, Propagate, Pulm Reviews, Pulmatrix, Quadrant, Reckner Associates, Recruiting Resource, Convergent Health Solutions, Sacoor, Sankyo, Sarasota Memorial Hospital, Schering, Schlesinger Medical, Scimed, Smith Research, Spanish Thoracic Society, Strategic North, Sudler and Hennessey, Summer Street Research, Synapse, Talecris, Theravance, ThinkEquity, University of British Columbia, University of Pittsburgh, University of California-Davis, UBC, UBS, Uptake Medical, and Vantage Point Management.

S. Rennard's institution has received grant support from NHLBI, Nebraska DHHS, Otsuka, Pfizer, GSK, Boehringer Ingelheim, Nycomed, Astra-Zeneca, Centocor, and Almirall. He has also received industry-sponsored grants from AstraZeneca, Biomarck, Centocor, Mpex, Nabi, Novartis, Otsuka. In addition he has consulted or participated in advisory boards for Able Associates, Adelpia Research, Almirall/Prescott, APT Pharma/Britnall, Aradigm, AstraZeneca, Boehringer Ingelheim, Chiesi, CommonHealth, Consult Complete, COPDForum, DataMonitor, Decision Resources, Defined Health, Dey, Dunn Group, Eaton Associates, Equinox, Gerson, GlaxoSmithKline, Informed, KOL Connection, M. Pankove, MedaCorp, MDRx Financial, Mpex, Novartis, Nycomed, Oriel Therapeutics, Otsuka, Pennside Partners, Pfizer (Varenicline), PharmaVentures, Pharmaxis, Price Waterhouse, Propagate, Pulmatrix, Reckner Associates, Recruiting Resources, Roche, Schlesinger Medical, Scimed, Sudler and Hennessey, TargeGen, Theravance, UBC, Uptake Medical, VantagePoint Management. SR has given lectures for: American Thoracic Society, AstraZeneca, Boehringer Ingelheim, California Allergy Society, Creative Educational Concept, France Foundation, Information TV, Network for Continuing Ed, Novartis, Pfizer, and SOMA.

**W. MacNee** has been reimbursed for travel by GlaxoSmithKline, Zambon, AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, Janssen and Micromet for attending and/or presenting at conferences. He has also received honoraria from

GlaxoSmithKline and AstraZeneca for participating as a speaker in scientific meetings and he serves on advisory boards for GlaxoSmithKline, Pfizer, Novartis, Ammirall, Amgen, Bayer and Micromet. W. MacNee also serves as a consultant for Pfizer and SMB Pharmaceuticals. He has received payment from GSK, Pfizer for research programmes and clinical activities.

**B.E. Miller** is an employee and shareholder of GlaxoSmithKline, the sponsor of ECLIPSE. His spouse is also an employee of GSK and holds stock and stock options in GSK.

**H. Müllerova** is an employee and shareholder of GlaxoSmithKline, the sponsor of ECLIPSE.

**R. Tal-Singer** is an employee and shareholder of GlaxoSmithKline, the sponsor of ECLIPSE.

**J. Vestbo** has received fees for advising and/or presenting from GlaxoSmithKline, AstraZeneca, Pfizer, Bioxydyn, Boehringer Ingelheim, Nycomed, Hoffmann-La Roche, Talecris, Kamada and Sounds Biotech. He has also received research support from GlaxoSmithKline. He has also received an unconditional grant in 1985 from a charity foundation fully funded by Scandinavian Tobacco Company. J. Vestbo's spouse has worked in the pharmaceutical industry, including GlaxoSmithKline.

**E. Wouters** serves on an advisory board for Nycomed; has received lecture fees from GlaxoSmithKline, AstraZeneca and Novartis; has received research grants from GlaxoSmithKline and AstraZeneca.

**J.C. Yates** is an employee and shareholder of GlaxoSmithKline, the sponsor of ECLIPSE.